A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Esmethadone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Acronyms RELIANCE-OLS
- Sponsors Relmada Therapeutics
- 20 Sep 2023 Results presented in a Relmada Therapeutics media release.
- 08 Aug 2023 According to a Relmada Therapeutics media release, Reliance-OLS (study 310), with REL-1017 was recently completed, and we are preparing for the availability of data from that study during the current quarter.
- 08 Aug 2023 Status changed to completed, according to a Relmada Therapeutics media release.